Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Mucociliary ClearanceClosed to enrollment Location: USA

    Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF) , protocol number Parion PS-G201

    This trail will look at the safety of the drug P-1037 and its effectiveness in combination with the drug hypertonic saline. The trail is estimated to last 5 weeks. It is for people with CF age 12 years and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      4

    • Length of Participation:

      5 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveClosed to enrollment Location: USA

    AeroVanc for the treatment of MRSA in people with CF , protocol number Savara SAV005-02

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of AeroVanc in treating persistent MRSA lung infections in people with cystic fibrosis.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30 to 100%

    • Number of Visits:

      9

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: USA

    SHIP: Study of hypertonic saline in preschoolers , protocol number NCT02378467 SHIP01

    This SHIP study evaluated the safety and effectiveness of hypertonic saline (7%) in pre-school children with CF.

    • Age:

      3 Years to 5 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 99%

    • Number of Visits:

      6

    • Length of Participation:

      54 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryCompleted with results Location: USA

    Phase 2 Study of inhaled Alpha-1 HC in people with CF , protocol number Grifols T6005-201

    This study took place at multiple care centres across the US. It looked at the safety and tolerability of inhaled Alpha-1 HC administered once a day for three weeks in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      9 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Phase 2 Study of Inhaled Nitric Oxide in People with CF , protocol number NCT02498535

    This study is taking place at multiple care centres across the US. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      35-85%

    • Number of Visits:

      10

    • Length of Participation:

      43 days

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Phase 2 study of oral glutathione in children with cystic fibrosis. , protocol number GROW-IP-16 NCT03020719

    This study evaluated the safety and effectiveness of the oral drug glutathione in children with cystic fibrosis who use pancreatic enzyme replacement therapy (PERT).

    • Age:

      24 months - 10 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      4

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Vitamin D for enhancing the immune system in people with CF , protocol number NCT01426256 TANGPR11A0

    This study evaluated the effect of a single high-dose of vitamin D3 given at the start of a pulmonary exacerbation followed by vitamin D3 maintenance treatment in adults with CF.

    • Age:

      16 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      20% or greater

    • Number of Visits:

      6

    • Length of Participation:

      1 year

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15

    This phase 2 study is taking place at multiple care centers across the US. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Arikace compared to TobiĀ® in people with CF with chronic Pseudomonas aueruginosa infections , protocol number NCT01315678 Insmed TR02-108

    This study looked at the effectiveness, safety and tolerability of Arikayce compared to a currently available antibiotic, TOBI (tobramycin inhalation solution). This study was for people with CF with chronic lung infections.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      11

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency , protocol number Axcan UMT20CF07-01

    This study looked at the effectiveness and safety of pancrelipase (ULTRASE MT20) in children who have CF and pancreatic insufficiency.

    • Age:

      7 Years to 11 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      33 days

    Contact us about this clinical Trial >
  • Displaying results 161-170 (of 191)
     |<  <  11 - 12 - 13 - 14 - 15 - 16 - 17 - 18 - 19 - 20  >  >|